AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Unstoppable Wiz: Cyber startup nets another $1 billion in funding as valuation jumps to $12B
2
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
3
Akamai acquiring cyber startup Noname Security for $450 million
4
Moritz code: Inside the mind of the best VC investor ever
5
Wiz deal to acquire Lacework collapses
More news

Pharmaceuticals

20 stories about Pharmaceuticals
default image

Following Restructuring Announcements, Teva Reinstated as Israel’s Biggest Company

18.12.17|Lilach Baumer
Teva's stock jumped 18.7% on the New York Stock Exchange between Thursday market opening and Friday market close. Israeli Prime Minister Benjamin Netanyahu is expected to meet with CEO Kåre Schultz Tuesday
אחרי ה שביתה נתב"ג טבע פיטורים טיסות טרמינל

Tel Aviv Airport, Stock Market Open as Solidarity Strike Ends

17.12.17|Lior Gutman, Omri Milman and Micky Grunfeld
Israel’s largest labor union called for a half-day strike on Thursday, in support of Teva employees
פסקל סוריו מנכ"ל AstraZeneca

Once Future CEO Could have Taken Teva on a Different Path

14.12.17|Lilach Baumer, Golan Hazani, and Orr Hirschauge
AstraZeneca CEO Pascal Soriot, which backed out of Teva’s CEO position in July, planned on taking the company towards innovation instead of generic focus
מנכ"ל טבע החדש קור שולץ 2

Teva to Cut Around Half of Israeli Workforce, Outsource Operations

13.12.17|Dror Reich
An internal document reviewed by Calcalist reveals the troubled drugmaker's detailed domestic cost-cutting plans
מפעל טבע טק ב רמת חובב

Teva to Cut Jobs, Shut Down Some Israeli Operations

13.12.17|Dror Reich and Sefi Krupsky
On Thursday, the troubled drugmaker is expected to unveil its cutback plan. At its center is extensive layoffs and the reorganization and divestment of non-core assets
יצחק פטרבורג

Former Chairman Yitzhak Peterburg Leaves Teva

13.12.17|Lilach Baumer
Mr. Peterburg was the troubled drugmaker's interim CEO between February and November 1, when Kåre Schultz took helm
מנכ"ל טבע החדש קור שולץ 1

Teva to Unveil Strategic Plan, Layoffs Thursday

12.12.17|Dror Reich
Last month the debt-riddled drug maker announced a rehabilitation plan amidst rumors of upcoming employee cuts
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
חברת ה תרופות טבע Teva

Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker

30.11.17|Anat Rouah
Tel Aviv-based capital investment firm Tulip Capital is threatening derivative action against Teva, saying the company's huge debt load renders its dividends unlawful
מנכ"ל טבע החדש קור שולץ

New CEO Steers Teva Back to Generics

28.11.17|Golan Hazani and Dror Reich
A reorganization plan announced by the company Monday would see the troubled drugmaker return to its core competencies, despite market pressures
default image

Biomed Company Protalix to Lay Off a Fifth of its Workforce

26.11.17|Dror Reich
The Israel-based NYSE American-listed company is currently undergoing a streamlining process
חממה של BOL קנאביס

Cannabis Breeder Barney's Farm Invests in Israeli Cannabis Company

23.11.17|Dror Reich
Barney's made a strategic investment of $2.1 million in Tel Aviv-listed Medivie Therapeutic Ltd., a company setting up a medical cannabis farm and pharmacy venture
default image

Perrigo Completes Sale of Israel Business for $110 million

23.11.17|Lilach Baumer
The buyer, New York-based investment firm SK Capital, has $1.9 billion assets under management
מנכ"ל טבע החדש קור שולץ 2

Troubled Drugmaker Teva to Axe over 4,000 Jobs

23.11.17|Golan Hazani
Less than a month after stepping in as CEO, Kåre Schultz starts tightening the belt. The company is expected to oust Chief Scientific Officer Michael Hayden
ראג'יב מאליק נשיא מיילן

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich
Mylan is currently the highest valued company on the TASE at $18.5 billion
תרופות טבע גלולות תרופה

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer
The clinical stage company develops treatments mostly for osteoporosis and bone disorders
מטה טבע פתח תקווה

Fitch Downgrades Teva to Junk Rating

07.11.17|Yaniv Rahimi
The U.S. credit agency changed Teva's rating from BBB to BB, with a negative outlook, due to "significant operational stress." The downgrade might affect Teva's ability to take on additional debt
מפעל טבע נתניה

There May Be a Silver Lining to Teva’s Woes

06.11.17|Eli Shimony
Analysts have lowered their target price for Teva following the company's less than stellar third quarter reports, but the company can still turn its luck around with new drugs and a willingness to tighten the belt
מטה טבע פתח תקווה

Allergan Planning Sale of its Teva Stock

01.11.17|Dror Reich and Lilach Baumer
For the third quarter of 2017, Allergan reported an operating loss of $4.02 billion, $1.3 billion of which is due to the depreciation of its Teva securities.
מנכ"ל טבע החדש קור שולץ

New CEO to Take Helm at Troubled Teva Wednesday

31.10.17|Lilach Baumer
The generic drugmaker shed 67% of its market price over the last 12 months
Previous ArticlesMore Articles